Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024.

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its new Roche Diagnostics Head Office in China.

Original from: BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended Septemb..

Original from: QuidelOrtho Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) · Reported revenue was $727 million - Recurring revenue1 w..

As of 31 October, 2024, all mainland-listed Chinese IVD companies have released their third-quarter financial reports. This summary provides insights into 50 main IVD enterprises and 20 IVD-related enterprises for ref..

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.

Orginal from: Qiagen · Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 · Net sales of $502 millio..

CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use.

Mindary Q3 Report: Operating Income Reaches ¥29.48 Billion Mindary has released its Q3 2024 results, revealing strong performance in the first three quarters of the year. The company ..

Original from: Revvity · Revenue of $684 million; 2% reported growth; 2% organic growth · GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 · Raises full year 2024 adjust..

Original from: Illumina · Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis · Core Illumina GAAP operating margin of 68.6% and non-GAAP oper..

Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced new data demonstrating that the company’s blood-biomarker alpha synuclein (α-synuclein) signatures accurately detect the aggregation of α-synuclein in the brain from a simple blood draw. Results from the study, which will be shared in a poster presentation (#116) on October 31 at the Clinical Trials on Alzheimer’s Disease (CTAD) international conference, demonstrate that Sunbird’s technology could provide blood-based diagnosis of multiple neurodegenerative diseases, including Parkinson’s disease, with high accuracy.

As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure. WHO’s EUL is based on the review of quality, safety and performance data in compliance with international standards while addressing the specific needs of low- and middle-income countries (LMICs).

Wolfe Research said Thursday that it has upgraded Danaher's shares to an Outperform rating from Peer Perform as the firm's growth is improving and it has capital to deploy.